JP2023532273A5 - - Google Patents
Info
- Publication number
- JP2023532273A5 JP2023532273A5 JP2022579927A JP2022579927A JP2023532273A5 JP 2023532273 A5 JP2023532273 A5 JP 2023532273A5 JP 2022579927 A JP2022579927 A JP 2022579927A JP 2022579927 A JP2022579927 A JP 2022579927A JP 2023532273 A5 JP2023532273 A5 JP 2023532273A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific
- cytokine fusion
- fusion according
- cancer
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043227P | 2020-06-24 | 2020-06-24 | |
| US63/043,227 | 2020-06-24 | ||
| US202063093724P | 2020-10-19 | 2020-10-19 | |
| US63/093,724 | 2020-10-19 | ||
| US202063094322P | 2020-10-20 | 2020-10-20 | |
| US63/094,322 | 2020-10-20 | ||
| US202163165738P | 2021-03-24 | 2021-03-24 | |
| US202163165600P | 2021-03-24 | 2021-03-24 | |
| US63/165,600 | 2021-03-24 | ||
| US63/165,738 | 2021-03-24 | ||
| PCT/CA2021/050872 WO2021258213A1 (en) | 2020-06-24 | 2021-06-24 | Bifunctional superkines and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532273A JP2023532273A (ja) | 2023-07-27 |
| JP2023532273A5 true JP2023532273A5 (enExample) | 2024-07-01 |
Family
ID=79282489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579927A Pending JP2023532273A (ja) | 2020-06-24 | 2021-06-24 | 二重特異性スーパーカイン及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230365642A1 (enExample) |
| EP (1) | EP4172216A4 (enExample) |
| JP (1) | JP2023532273A (enExample) |
| CN (1) | CN116390744A (enExample) |
| CA (1) | CA3183825A1 (enExample) |
| WO (1) | WO2021258213A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104619334A (zh) | 2012-08-09 | 2015-05-13 | 利兰斯坦福初级大学董事会 | 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| US20230242607A1 (en) * | 2020-07-09 | 2023-08-03 | Eutilex Co., Ltd. | Il-2 variants |
| TW202317623A (zh) * | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250387474A1 (en) * | 2022-03-08 | 2025-12-25 | Medicenna Therapeutics Inc. | Uses and methods for il-2, il-13, and il-4 cytokine bifunctional molecules |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023248009A1 (en) * | 2022-06-21 | 2023-12-28 | Medicenna Therapeutics, Inc. | Dosing methods for use with il-2 superagonists, agonists, and fusions thereof |
| WO2024073435A2 (en) * | 2022-09-27 | 2024-04-04 | Anwita Biosciences, Inc. | Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2025003770A2 (en) * | 2023-06-27 | 2025-01-02 | Medicenna Therapeutics Inc. | Il-2 fusion proteins |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2850093B1 (en) * | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| US12590133B2 (en) * | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) * | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
-
2021
- 2021-06-24 CN CN202180050945.2A patent/CN116390744A/zh active Pending
- 2021-06-24 JP JP2022579927A patent/JP2023532273A/ja active Pending
- 2021-06-24 US US18/002,824 patent/US20230365642A1/en active Pending
- 2021-06-24 CA CA3183825A patent/CA3183825A1/en active Pending
- 2021-06-24 EP EP21828793.6A patent/EP4172216A4/en active Pending
- 2021-06-24 WO PCT/CA2021/050872 patent/WO2021258213A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532273A5 (enExample) | ||
| JP2020524174A5 (enExample) | ||
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| DeVita et al. | The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture | |
| Hoyos et al. | Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety | |
| Dasgupta et al. | Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer | |
| JP2020522254A5 (enExample) | ||
| Kuo et al. | Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells | |
| JP2021524756A5 (enExample) | ||
| Buhmann et al. | Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial | |
| JP2022521937A5 (enExample) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| JP2022532490A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| Ouladan et al. | Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy | |
| Warmuth et al. | Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| Zhu et al. | CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer | |
| Lutz et al. | IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer | |
| Liu et al. | A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities | |
| Zorko et al. | Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? | |
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| Yu et al. | Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma | |
| Prodi et al. | Tumor-homing antibody-cytokine fusions for cancer therapy | |
| Zhao et al. | Current status and future perspective of natural killer cell therapy for cancer |